In fact, only the TP53 mutation (i.e., the founder) exhibited a steep drop after surgery for GC1, while SLCOB1 (i.e., non-founder) remained negative, suggesting that genetic tumor heterogeneity may have affected ctDNA release from the primary tumor. Here, TP53 is linked to neoplasm.